For tendon injuries accompanied by significant inflammation, adding TB-500 provides complementary benefit
Two phase II trials - one in a population with obesity (without T2D) [45], and a second in a population with T2D and overweight/obesity [46], have recently been published and their key findings are presented below (Table 1)
The last compound, an isomer of octane, is nearly spherical and has an exceptionally high melting point (only 6 below the boiling point)
Therapeutic and safety assessments The final all-randomized analysis sample included 96 participants from Beijing Stomatological Hospital (investigator-initiated trial) and 36 participants from Peking University Third Hospital (Phase I trial) (Fig
After your blood draw, just hang tight and don't worry - we'll keep you updated and in the loop
These data are illustrated in Figure 3